FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1484121608> ?p ?o ?g. }

• W1484121608 endingPage "2157" @default.
• W1484121608 startingPage "2152" @default.
• W1484121608 abstract "BACKGROUND. Despite advances in first-line therapy, there are few data on treatment of glioblastoma multiforme (GBM) at recurrence. Temozolomide (TMZ) is well tolerated and may have activity despite prior TMZ exposure if novel dose schedules are used. METHODS. The authors reviewed their experience with a continuous TMZ schedule (50 mg/m2 daily), given at progression after conventional 5-day TMZ. Patients were reported in 3 groups: 1) GBM after progression on conventional TMZ; 2) GBM at first recurrence after completion of standard concomitant and adjuvant TMZ; and 3) patients with other anaplastic gliomas at second relapse on conventional TMZ. RESULTS. In Group 1, 21 patients with a median age of 54 years (range, 33 years-68 years) received a median of 3 cycles (range, 2-12 cycles) of continuous TMZ at 50 mg/m2. Overall clinical benefit (complete response, partial response, and stable disease) was 47%, with 6-month progression-free survival (PFS) of 17%. In Group 2, 14 patients with GBM, median age 52 years (range, 38 years-62 years) received continuous TMZ at progression after initial TMZ/radiotherapy (RT) and adjuvant TMZ. The median interval after adjuvant TMZ was 3 months (range, 2 months-10 months). A median of 5 cycles of TMZ was given, and 6-month PFS was 57%. In Group 3, 14 patients with a median age of 49 years (range, 34 years-56 years) received continuous TMZ; 2 partial responses and 6 with stable disease were seen, with a 6-month PFS of 42%. Toxicities were mild and well tolerated; lymphopenia was common but no serious opportunistic infections were identified. CONCLUSIONS. Although retrospective, our results demonstrate that continuous daily administration of TMZ is an active regimen despite prior TMZ therapy. The excellent tolerability of this regimen may allow future combination with other alkylating agents or with novel therapies. Cancer 2008. © 2008 American Cancer Society." @default.
• W1484121608 created "2016-06-24" @default.
• W1484121608 creator A5000656122 @default.
• W1484121608 creator A5022846191 @default.
• W1484121608 creator A5060818073 @default.
• W1484121608 creator A5061428705 @default.
• W1484121608 creator A5087695200 @default.
• W1484121608 date "2008-10-15" @default.
• W1484121608 modified "2023-10-15" @default.
• W1484121608 title "Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule" @default.
• W1484121608 cites W1959628099 @default.
• W1484121608 cites W1970721581 @default.
• W1484121608 cites W1978661277 @default.
• W1484121608 cites W1984955359 @default.
• W1484121608 cites W2039289142 @default.
• W1484121608 cites W2059624809 @default.
• W1484121608 cites W2079269416 @default.
• W1484121608 cites W2096287682 @default.
• W1484121608 cites W2105100844 @default.
• W1484121608 cites W2109176505 @default.
• W1484121608 cites W2121276929 @default.
• W1484121608 cites W2135533113 @default.
• W1484121608 cites W2139671097 @default.
• W1484121608 cites W2143665087 @default.
• W1484121608 cites W2169965478 @default.
• W1484121608 doi "https://doi.org/10.1002/cncr.23813" @default.
• W1484121608 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18756530" @default.
• W1484121608 hasPublicationYear "2008" @default.
• W1484121608 type Work @default.
• W1484121608 sameAs 1484121608 @default.
• W1484121608 citedByCount "114" @default.
• W1484121608 countsByYear W14841216082012 @default.
• W1484121608 countsByYear W14841216082013 @default.
• W1484121608 countsByYear W14841216082014 @default.
• W1484121608 countsByYear W14841216082015 @default.
• W1484121608 countsByYear W14841216082016 @default.
• W1484121608 countsByYear W14841216082017 @default.
• W1484121608 countsByYear W14841216082018 @default.
• W1484121608 countsByYear W14841216082019 @default.
• W1484121608 countsByYear W14841216082020 @default.
• W1484121608 countsByYear W14841216082021 @default.
• W1484121608 countsByYear W14841216082022 @default.
• W1484121608 countsByYear W14841216082023 @default.
• W1484121608 crossrefType "journal-article" @default.
• W1484121608 hasAuthorship W1484121608A5000656122 @default.
• W1484121608 hasAuthorship W1484121608A5022846191 @default.
• W1484121608 hasAuthorship W1484121608A5060818073 @default.
• W1484121608 hasAuthorship W1484121608A5061428705 @default.
• W1484121608 hasAuthorship W1484121608A5087695200 @default.
• W1484121608 hasConcept C126322002 @default.
• W1484121608 hasConcept C141071460 @default.
• W1484121608 hasConcept C143998085 @default.
• W1484121608 hasConcept C2776694085 @default.
• W1484121608 hasConcept C2777389519 @default.
• W1484121608 hasConcept C2777863537 @default.
• W1484121608 hasConcept C2778227246 @default.
• W1484121608 hasConcept C2778880634 @default.
• W1484121608 hasConcept C2779083369 @default.
• W1484121608 hasConcept C2779384505 @default.
• W1484121608 hasConcept C2780739268 @default.
• W1484121608 hasConcept C2780964509 @default.
• W1484121608 hasConcept C502942594 @default.
• W1484121608 hasConcept C509974204 @default.
• W1484121608 hasConcept C71924100 @default.
• W1484121608 hasConceptScore W1484121608C126322002 @default.
• W1484121608 hasConceptScore W1484121608C141071460 @default.
• W1484121608 hasConceptScore W1484121608C143998085 @default.
• W1484121608 hasConceptScore W1484121608C2776694085 @default.
• W1484121608 hasConceptScore W1484121608C2777389519 @default.
• W1484121608 hasConceptScore W1484121608C2777863537 @default.
• W1484121608 hasConceptScore W1484121608C2778227246 @default.
• W1484121608 hasConceptScore W1484121608C2778880634 @default.
• W1484121608 hasConceptScore W1484121608C2779083369 @default.
• W1484121608 hasConceptScore W1484121608C2779384505 @default.
• W1484121608 hasConceptScore W1484121608C2780739268 @default.
• W1484121608 hasConceptScore W1484121608C2780964509 @default.
• W1484121608 hasConceptScore W1484121608C502942594 @default.
• W1484121608 hasConceptScore W1484121608C509974204 @default.
• W1484121608 hasConceptScore W1484121608C71924100 @default.
• W1484121608 hasIssue "8" @default.
• W1484121608 hasLocation W14841216081 @default.
• W1484121608 hasLocation W14841216082 @default.
• W1484121608 hasOpenAccess W1484121608 @default.
• W1484121608 hasPrimaryLocation W14841216081 @default.
• W1484121608 hasRelatedWork W2070226426 @default.
• W1484121608 hasRelatedWork W2081797247 @default.
• W1484121608 hasRelatedWork W2119925221 @default.
• W1484121608 hasRelatedWork W2120328604 @default.
• W1484121608 hasRelatedWork W2130852442 @default.
• W1484121608 hasRelatedWork W2157027442 @default.
• W1484121608 hasRelatedWork W2314557535 @default.
• W1484121608 hasRelatedWork W4237783004 @default.
• W1484121608 hasRelatedWork W4256289735 @default.
• W1484121608 hasRelatedWork W59994307 @default.
• W1484121608 hasVolume "113" @default.
• W1484121608 isParatext "false" @default.
• W1484121608 isRetracted "false" @default.
• W1484121608 magId "1484121608" @default.

• next